Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02220127 : RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Adult patients with brain metastasis from any primary tumour receiving GKR.

- All intracranial micro-metastases including lesions located in the cerebral
hemispheres, thalamus, basal ganglia and cerebellum and excluding lesions located in
the brain stem below the level of the superior colliculi.

- Target volume < 0.14 cc3 and maximum diameter < 7 mm.

- The subject consents to participate in the study.

Exclusion Criteria:

- Inability to consent

- Younger than 18 years of age.

- Lesions in the brainstem (below the level of the superior colliculi) are better
treated with the 4 mm collimator and they will be excluded from the study.

- Patients with more than 25 brain lesions suitable for randomisation will be excluded
from the study.

- Co-morbidity or previous treatment such as surgery, chemotherapy or WBRT is not to be
considered as exclusion criteria.

- Pregnancy in the context of brain metastases is not a contraindication for GKR, and
therefore it will not be considered as exclusion criteria for this trial.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557